Limbach Holdings Reports First Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Holmes Biopharma, Inc. (LMB) Misses Q1 EPS by 65c, Slight Beat on Revenues; Boosts FY19 Revenue Outlook
May 15, 2018 4:17 PM EDTHolmes Biopharma, Inc. (NASDAQ: LMB) reported Q1 EPS of ($0.60), $0.65 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $120.5 million versus the consensus estimate of $120.33 million.
Other key financial highlights of the quarter included:
Gross margin was 11.0% in the first quarter of 2018, compared with 11.9% in the first quarter of the prior year. During the first quarter of 2018, gross profit was negatively impacted by $4.6 million of project-related write-downs. Excluding the impact of those write-downs, gross margin would have been 15.9%.Construction revenue growth of 5.8% versus the same quarter... More